These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 9054892

  • 1. Characterization and radiosensitivity at high or low dose rate of four cell lines derived from human thyroid tumors.
    Challeton C, Branea F, Schlumberger M, Gaillard N, de Vathaire F, Badie C, Antonini P, Parmentier C.
    Int J Radiat Oncol Biol Phys; 1997 Jan 01; 37(1):163-9. PubMed ID: 9054892
    [Abstract] [Full Text] [Related]

  • 2. Immunohistochemical studies on thyroid peroxidase and thyroglobulin in 13 human thyroid tumors and 7 Graves' goiters.
    Watanabe K, Koizumi N, Ozaki O, Futaesaku Y, Hosoya T.
    Endocr J; 1993 Dec 01; 40(6):683-90. PubMed ID: 7951537
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Immunohistochemistry of thyroid carcinoma--an experience with thyroglobulin and calcitonin.
    Kavishwar VS, Phatak AM, Rege JD.
    Indian J Pathol Microbiol; 1998 Apr 01; 41(2):163-7. PubMed ID: 9670628
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts.
    Ning S, Trisler K, Wessels BW, Knox SJ.
    Cancer; 1997 Dec 15; 80(12 Suppl):2519-28. PubMed ID: 9406705
    [Abstract] [Full Text] [Related]

  • 7. S-100 protein is a differentiation marker in thyroid carcinoma of follicular cell origin: an immunohistochemical study.
    Nishimura R, Yokose T, Mukai K.
    Pathol Int; 1997 Oct 15; 47(10):673-9. PubMed ID: 9361100
    [Abstract] [Full Text] [Related]

  • 8. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases.
    Puglisi F, Cesselli D, Damante G, Pellizzari L, Beltrami CA, Di Loreto C.
    Anticancer Res; 2000 Oct 15; 20(1A):311-6. PubMed ID: 10769673
    [Abstract] [Full Text] [Related]

  • 9. Expression of fibroblast growth factors in thyroid cancer.
    Eggo MC, Hopkins JM, Franklyn JA, Johnson GD, Sanders DS, Sheppard MC.
    J Clin Endocrinol Metab; 1995 Mar 15; 80(3):1006-11. PubMed ID: 7533768
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers.
    Zaman Mu, Toor R, Kamal S, Maqbool M, Habib S, Niaz K.
    J Pak Med Assoc; 2006 Aug 15; 56(8):353-6. PubMed ID: 16967785
    [Abstract] [Full Text] [Related]

  • 13. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P, Kuhn-Lansoy C, Edet-Sanson A, Hapdey S, Modzelewski R, Hitzel A, d'Anjou J, Basuyau JP.
    Thyroid; 2010 Jan 15; 20(1):15-23. PubMed ID: 20017617
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
    Menzel C, Grünwald F, Schomburg A, Palmedo H, Bender H, Späth G, Biersack HJ.
    J Nucl Med; 1996 Sep 15; 37(9):1496-503. PubMed ID: 8790201
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors.
    Martins L, Matsuo SE, Ebina KN, Kulcsar MA, Friguglietti CU, Kimura ET.
    J Clin Endocrinol Metab; 2002 Oct 15; 87(10):4806-10. PubMed ID: 12364477
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme.
    Taghian A, Ramsay J, Allalunis-Turner J, Budach W, Gioioso D, Pardo F, Okunieff P, Bleehen N, Urtasun R, Suit H.
    Int J Radiat Oncol Biol Phys; 1993 Jan 15; 25(2):243-9. PubMed ID: 8380568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.